Skip to main content

UM School of Medicine Awarded $3.5 Million in Federal Funding to Expand Medical Countermeasures Program

February 26, 2024 | Deborah Kotz

Erika Davies, PhDUniversity of Maryland School of Medicine (UMSOM) Dean Mark T. Gladwin, MD, announced  today that UMSOM  faculty scientists have been selected as key contractors by the Biomedical Advanced Research and Development Authority (BARDA), for the federal agency’s Radiation Nuclear Animal Model Development program. The $3.5 million award that Erika Davies, PhD, Assistant Professor of Radiation Oncology, received to develop Acute Radiation Syndrome Animal Models, has a $16 million potential total. The Division of Translational Radiation Sciences (DTRS), within the Department of Radiation Oncology, will support this project.

Dr. Davies and her colleagues are working with BARDA to advance the development of radiologic and nuclear countermeasures. This is part of a broader effort to enhance national preparedness for radiation accidents and emergencies. We’re trying to develop and test new treatments that can be used in a terror attack scenario that involves high radiation exposure,” said Dr. Davies.  “We are developing robust animal models that will translate well to humans.”

BARDA is part of the Office of the Secretary for Preparedness and Response in the U.S. Department of Health and Human Services (DHHS).

William F. Regine, MD, FACR, FACROCurrently, relatively few medical treatments are available to counter radiological and nuclear threats as FDA approval requires extensive preclinical efficacy and safety data to support drug approval. Many more such agents are needed, based on the range of options that could be employed by terrorists, the need for urgent intervention following radiation exposure, and the medical complexities of acute and chronic radiation injury.

“The DTRS is uniquely positioned to provide leading expertise in medical countermeasures research,” said William Regine, MD, the Isadore & Fannie Schneider Foxman Chair of Radiation Oncology at UMSOM. “We are bridging first-in-class radiation science with contract research to increase the likelihood of survival in a radiation or nuclear incident, while simultaneously identifying a potential new class of therapeutics for cancer patients undergoing radiation therapy.”

Mark T. Gladwin, MDAlmost a decade ago research by DTRS faculty and staff led to the approval of the first drug to treat the deleterious effects of radiation exposure following a nuclear incident based on efficacy data generated in animal models. Animal models are especially important in preparing for radiation emergencies, because the efficacy of most experimental treatments cannot be tested in humans.

“DTRS is able to develop different experimental models through its world class ‘Good Laboratory Practice’-compliant testing facility, which houses one of the nation’s most well-equipped suites of technologies supporting radiation research,” said Dr. Gladwin who is the John Z. and Akiko K. Bowers Distinguished Professor and Dean of UMSOM, and Vice President for Medical Affairs at University of Maryland, Baltimore“Our faculty’s collaborative expertise from across the broadest spectrum of countermeasure investigations, allow the rapid configuration and implementation of solutions-oriented approaches to even the most difficult challenges.”

The work with BARDA will include multiple individual projects that draw on changing configurations of DTRS experts, instrumentation, and specialized resources, as well as on collaborations with other UMSOM and University of Maryland, Baltimore investigators.

About the University of Maryland School of Medicine

Now in its third century, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States. It continues today as one of the fastest growing, top-tier biomedical research enterprises in the world -- with 46 academic departments, centers, institutes, and programs, and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academy of Medicine and the National Academy of Sciences, and a distinguished two-time winner of the Albert E. Lasker Award in Medical Research. With an operating budget of more than $1.2 billion, the School of Medicine works closely in partnership with the University of Maryland Medical Center and Medical System to provide research-intensive, academic, and clinically based care for nearly 2 million patients each year. The School of Medicine has more than $500 million in extramural funding, with most of its academic departments highly ranked among all medical schools in the nation in research funding. As one of the seven professional schools that make up the University of Maryland, Baltimore campus, the School of Medicine has a total population of nearly 9,000 faculty and staff, including 2,500 students, trainees, residents, and fellows. The School of Medicine, which ranks as the 8th highest among public medical schools in research productivity (according to the Association of American Medical Colleges profile) is an innovator in translational medicine, with 606 active patents and 52 start-up companies. In the latest U.S. News & World Report ranking of the Best Medical Schools, published in 2023, the UM School of Medicine is ranked #10 among the 92 public medical schools in the U.S., and in the top 16 percent (#32) of all 192 public and private U.S. medical schools. The School of Medicine works locally, nationally, and globally, with research and treatment facilities in 36 countries around the world. Visit medschool.umaryland.edu

Contact

Deborah Kotz
dkotz@som.umaryland.edu
410-706-4255

Related stories

    Friday, October 11, 2019

    New Treatment Combination Could Work Against Broader Array of Cancer Cells, Study Finds

    In continuing efforts to find novel ways to kill cancer cells, researchers at the University of Maryland School of Medicine (UMSOM) have identified a new pathway that leads to the destruction of cancer cells. The new finding, published this week in the journal PNAS, could pave the way for the broader use of a class of anticancer drugs already on the market. These drugs, known as PARP inhibitors, are currently approved by the FDA to treat only a limited group of breast and ovarian cancers associated with BRCA gene mutations.


    Wednesday, July 31, 2019

    Inconsistent Reporting of Methodologies Makes Most Radiation Biology Studies Impossible to Replicate

    Nearly 80 percent of radiation oncology studies funded by the National Institutes of Health involve investigating the effects that radiation has on tumor cells and healthy tissue in pre-clinical settings, such as experiments done in cell cultures or mice. A majority of these radiation biology studies, however, have serious flaws in how their irradiation methodology is described, which makes them very difficult to replicate, according to a new finding from the University of Maryland School of Medicine (UMSOM).


    Tuesday, February 19, 2019

    Dr. Robert C. Miller, National Leader in Radiation Oncology, Named New Medical Director of Maryland Proton Treatment Center

    William F. Regine, MD, FACR, FACRO, The Isadore and Fannie Schneider Foxman Chair and Professor of Radiation Oncology at the University of Maryland School of Medicine (UMSOM), along with UMSOM Dean E. Albert Reece, MD, PhD, MBA, announced today that Robert C. Miller, MD, MBA, FASTRO a nationally-recognized radiation oncologist who currently serves as Vice Chair in the Department of Radiation Oncology at the Mayo Clinic, has been named Professor in the UMSOM Department of Radiation Oncology and Medical Director of the Maryland Proton Treatment Center (MPTC). He will begin his new position in April 2019.


    Monday, October 29, 2018

    UMSOM Honors Breast Cancer Awareness Month, Our Research Continues Toward Combating this Disease

    October is Breast Cancer Awareness Month, and researchers at the University of Maryland School of Medicine (UMSOM) continue in their work to help combat this disease that impacts more than 315,000 women in the U.S. each year.


    Monday, October 08, 2018

    High-Precision Proton Therapy More Effective in Treating Certain Cancers When Combined with Thermal Therapy

    The Maryland Proton Treatment Center (MPTC) is now offering deep-tissue external thermal therapy in combination with high-precision proton-beam radiotherapy as a potential way to boost survival chances for certain cancer patients. MPTC is the only center in the world to offer these two treatments at the same facility, an advantage to patients because these therapies are typically given within an hour of each other.


    Monday, September 24, 2018

    University of Maryland School of Medicine Researchers to Present Original Research at Key Radiation Conference

    The University of Maryland School of Medicine (UMSOM) announced that the Division of Translational Radiation Science (DTRS) will participate in the annual meeting of the Radiation Research Society (RRS) on September 23-26, 2018, in Chicago.


    Monday, May 14, 2018

    Gov. Larry Hogan Recognizes Achievements of Sally B. Cheston, MD, of Central Maryland Radiation Oncology Center

    Maryland Gov. Larry Hogan today recognized Sally B. Cheston, MD, an assistant professor of radiation oncology at the University of Maryland School of Medicine (UMSOM), for her efforts to bring the “latest state-of-the-art medicine” to Howard County as a leader of the Central Maryland Radiation Oncology Center (CMRO).


    Friday, January 15, 2016

    UM SOM to Participate in Expanded Medical Countermeasures Research Project

    University of Maryland School of Medicine (UM SOM) Department of Radiation Oncology Chair and Professor William F. Regine, MD, FACR, FACRO, and UM SOM Dean E. Albert Reece, MD, PhD, MBA, announced today that researchers at the UM SOM have been selected as key contractors by the Biomedical Advanced Research and Development Authority (BARDA), for its Radiation Nuclear Animal Model Development program. BARDA is part of the Office of the Secretary for Preparedness and Response in the U.S. Department of Health and Human Services (DHHS).